Combined FLT3-, BCL-2-, and Rac1 inhibition could re-establish drug sensitivity in a midostaurin (FLT3 inhibitor)-resistant MOLM-13 AML cell line [12]. The gene discussed is BCL2; the disease is acute myeloid leukemia.